Theralase Technologies (TSE:TLT) has released an update.
Theralase Technologies Inc. has announced a significant breakthrough in cancer treatment, revealing its lead compound, Rutherrin®, has shown preclinical success in targeting and destroying Non-Small Cell Lung Cancer. In experiments using a Lewis Lung Cancer model in mice, Rutherrin® demonstrated increased selectivity for cancer cells and, when activated by x-rays, resulted in all treated animals surviving and exhibiting substantially slower tumor growth compared to x-ray treatment alone.
For further insights into TSE:TLT stock, check out TipRanks’ Stock Analysis page.
